Samsung Bioepis Eyes China With 3SBio Deal

 
• By Dave Wallace

Samsung Bioepis has struck a licensing agreement with China’s 3SBio that will allow the firm to expand its biosimilars business into the Chinese market. Bevacizumab is among several biosimilar candidates covered by the deal.

ChinaHandshake
Samsung Bioepis Gains Access To China For Its Biosimilars • Source: Shutterstock

More from Biosimilars

More from Products